A Phase I Trial to Determine the Safety and Tolerability of Autophagy Inhibition Using Chloroquine or Hydroxychloroquine in Combination with Carboplatin and Gemcitabine in Patients with Advanced Solid Tumorsced solid tumors.
Nagla Abdel Karim(University of Cincinnati), John C. Morris(University of Cincinnati)
Cited by 3
Related Papers
Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
|BMC Cancer|2018|131
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
|Frontiers in Oncology|2021|26
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
|Journal of Clinical Oncology|2019|8
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
|Asian Pacific Journal of Cancer Prevention|2019|6